Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease

NCT01254773 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

146

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: Experimental Bapineuzumab

Sponsor

JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Collaborators

[object Object]